Evaluation status available after sign-in
About the journal
Oncolog-Hematolog.ro is an open-access journal published by Medichub Media in Romania, publishing in english. It is listed in DOAJ according to the sources read. Declared review time at DOAJ: 8 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Medichub Media
- ISSN
- 2066-8716 · 2066-8260
- Country
- Romania
- Languages
- english
- Access
- Open access
- Articles in DOAJ
- 146
- Declared review time
- 8 weeks
- Declared peer-review model
- other
- Official website
- https://medichub.ro/reviste-de-specialitate/oncolog-hematolog-ro
Index listings
- DOAJ · 2021-04-01
- Indexing
- DOAJ
- APC
- —
- Declared review time (DOAJ)
- 8 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
146
Most recent article
4 months ago
Average review time (journal-declared via DOAJ)
8weeks
Works in OpenAlex
458
Last recorded publication year
2025
Reported by OpenAlex in 1 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core
h-index
3
i10-index
0
From OpenAlex open data (CC0).
Editorial & policy8
- Last DOAJ review date
- 2021-04-01
- Added to DOAJ
- 2021-04-01
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 37%
- ORCID iDs in current deposits
- 0%
- Peer-review policy
- View policy
Identity & continuity1
- Source type
- journal
Classification2
Subjects (DOAJ)
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
LCC codes
RC254-282
Subject areas
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Pain Management and Opioid Use
- Palliative and Oncologic Care
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Palliative Care and End-of-Life Issues
- Palliative Care and End-of-Life Issues
Show all subjects (75)
- Acute Myeloid Leukemia Research
- Advances in Oncology and Radiotherapy
- Lung Cancer Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Palliative Care and End-of-Life Issues
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Renal cell carcinoma treatment
- Metastasis and carcinoma case studies
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Multiple and Secondary Primary Cancers
- Multiple and Secondary Primary Cancers
- Retinoids in leukemia and cellular processes
- Pancreatic and Hepatic Oncology Research
- Hematological disorders and diagnostics
- Cancer survivorship and care
- Cardiac tumors and thrombi
- Renal cell carcinoma treatment
- Breast Cancer Treatment Studies
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Colorectal Cancer Surgical Treatments
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Viral-associated cancers and disorders
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Sarcoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Breast Lesions and Carcinomas
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Medical Imaging and Pathology Studies
- Medical Imaging and Pathology Studies
- Colorectal and Anal Carcinomas
- BRCA gene mutations in cancer
- Management of metastatic bone disease
- BRCA gene mutations in cancer
- BRCA gene mutations in cancer
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Sarcoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Neuroendocrine Tumor Research Advances
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
Keywords (DOAJ)
- oncology
- hematology
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
Loading community confirmations…
The journal's record in other sources:Web of Science MJLDOAJ